
Peking University First Hospital has a total capacity of 1,805 beds across three campuses: Central, Miyun, and Daxing. The hospital delivers a full range of inpatient and outpatient services, serving patients across China and internationally.
Established in 1915, Peking University First Hospital (PUFH) is one of China's most prestigious medical institutions, affiliated with the Peking University Health Science Center. As a top-tier tertiary hospital classified as Grade 3A, it is recognized for its leadership in clinical excellence, education, and research. Over the decades, PUFH has been pioneering in shaping modern Chinese medicine, particularly in specialties such as urology, nephrology, pediatrics, neurology, cardiology, and organ transplantation.
The hospital is home to a team of highly qualified doctors and professors, including many national-level experts. Known for managing complex and rare diseases, it continues to advance patient care through innovation, multidisciplinary collaboration, and compassionate treatment.
Advanced Technology & Facilities
Key Services at Peking University First Hospital
Peking University First Hospital blends a century of medical heritage with high-quality clinical care, innovative research, and comprehensive education. It stands as a benchmark of excellence in China, committed to improving patient outcomes through multidisciplinary collaboration and compassionate, personalized care.

The hospital has approximately 50 inpatient beds in its main campus, along with nine satellite clinics across Beijing. It manages over 2,500 outpatient visits each week and provides care to hundreds of thousands of patients annually, both local and international.
Beijing United Family Hospital (BJU) is one of China’s most prestigious private medical institutions, known for delivering world-class healthcare that meets international standards. Established in 1997, it was the first foreign-invested hospital in China and has since become a trusted choice for both International and Chinese patients seeking high-quality, patient-focused care. As part of the United Family Healthcare network, BJU has built a reputation for medical excellence, advanced technology, and a uniquely personalized approach to treatment.
The hospital is staffed by a diverse team of internationally trained doctors, many of whom have practiced in top healthcare systems across the U.S., Europe, and Asia. This global expertise is complemented by the latest medical equipment, multilingual support services, and a strong commitment to clinical safety and patient satisfaction. Recognized by the Joint Commission International (JCI) for meeting the highest standards in healthcare delivery, BJU offers a full spectrum of medical services across numerous specialties, including family medicine, internal medicine, orthopedics, oncology, cardiology, obstetrics, pediatrics, and plastic surgery.
Advanced Technology & Facilities
Key Services at BJU
Beijing United Family Hospital stands as a pioneer in international-standard healthcare in China, blending modern technology, world-class medical expertise, and a warm, comprehensive approach to family health.

As part of Singapore‑listed Raffles Medical Group, founded in 1976, RMG China operates 5 tertiary hospitals and over 100 clinics, supported by 430+ physicians and 900+ nurses & allied health professionals, delivering comprehensive inpatient and outpatient services.
Raffles Medical Group has operated in China since 2010, growing into a trusted name among both local and expatriate communities. All RMG China hospitals and clinics follow the Group’s Institutional Group Practice Model, which emphasizes integrated, peer-reviewed, and clinically audited care. Backed by Raffles Hospital Singapore, accredited by Joint Commission International (JCI), the network ensures alignment with global standards for quality and patient safety. With a rigorous clinical governance framework, strategic insurance and corporate partnerships, and a presence in key Chinese cities, RMG serves over 2.8 million patients annually. The Group continues to expand across China, offering world-class healthcare that combines international expertise with localized, patient-centered care.
Advanced Technology & Facilities
Key Services at Raffles Medical Group China
Raffles Medical Group China is a leading integrated private hospital network, delivering high-quality, multidisciplinary medical care in major Chinese cities. With its robust institutional infrastructure, advanced diagnostic and treatment facilities, and a reputation anchored by the Singapore-based Raffles Hospital, RMG China continues to expand and uphold global healthcare standards.

GoBroad Healthcare Group, founded in 2017, is a leading medical network in China, specializing in the treatment of complex hematologic diseases and solid tumors. The group integrates clinical treatment, research, reference laboratories, and medical information technology under an Academic Research Organization model. With seven hospitals across Beijing, Shanghai, and Guangzhou, it provides advanced therapies including CAR-T cell therapy, hematopoietic stem cell transplantation, chemotherapy, radiotherapy, and targeted therapy. Its multidisciplinary teams ensure that patients receive comprehensive and personalized treatment for both common and rare conditions. The group is known for its patient-centered approach by combining modern medical science with innovative therapies and long-term follow-up care. With international collaborations, multilingual staff, and dedicated global patient services, it has become a trusted choice for individuals seeking specialized cancer and hematology treatments in China. By focusing on research-driven medicine, advanced facilities, and supportive care, GoBroad Healthcare Group continues to enhance patient survival, recovery, and long-term quality of life.
Advanced Technology & Facilities
Key Services



Beijing is widely trusted for hematologic malignancy care due to its concentration of national level hospitals, experienced subspecialty teams, and strong safety culture. Clinics in the city are typically part of large academic medical systems with access to advanced laboratories, imaging, and dedicated inpatient units for blood cancer treatment. Many follow nationally recognized accreditation and infection control standards, which is especially important for patients receiving intensive therapies.
Treatment for hematologic malignancy in Beijing typically ranges from USD 18,000 to USD 95,000. Final costs vary based on diagnosis, disease stage, use of stem cell transplantation or CAR T therapy, length of hospitalization, and the level of supportive care needed. Recovery often follows a milestone based pattern. The first week focuses on close monitoring, the first month involves immune recovery and follow up testing, and returning to full routines may take several months. Not every patient is an ideal candidate for advanced treatment, so each case requires individual assessment and a tailored plan by the clinic team.
This information is for educational purposes and does not replace an in person consultation with a qualified specialist.
Hematologic malignancy clinics in Beijing are known for experienced multidisciplinary teams, structured patient pathways, and well regulated hospital environments. Many centers treat high volumes of complex cases each year and maintain standardized protocols for diagnosis, treatment delivery, and long term follow up.
Peking University People’s Hospital Hematology Center is one of the most respected blood cancer centers in China. It treats leukemia, lymphoma, multiple myeloma, and related disorders using advanced diagnostics, targeted therapies, and CAR T immunotherapy. The center is well known for its stem cell transplantation programs and strict safety standards, including infection prevention and post treatment monitoring.
Beijing Lu Daopei Hospital is a specialized hospital dedicated entirely to hematologic diseases. It has comprehensive hematology wards, advanced laboratory capabilities, and strong experience in stem cell transplantation and cellular therapies. The hospital is often chosen for complex or relapsed cases due to its focused expertise and structured follow up systems.
Beijing Jingdu Children’s Hospital provides specialized care for pediatric hematologic malignancies. The hospital treats childhood leukemia and lymphoma and offers pediatric stem cell transplantation and immunotherapy options. Its care model emphasizes child focused safety measures, family communication, and long term developmental follow up.
Best Clinic Abroad supports international patients who are considering hematologic malignancy treatment in Beijing. The team helps connect you with verified clinics, clarify treatment options, and coordinate important details around your care journey.
➤ Initial virtual consultation - Arrange online discussions so clinics can review medical records and provide preliminary guidance.
➤ Clear package information - Request transparent cost estimates that outline typical inclusions such as hospital care, procedures, and follow up services.
➤ Medical file coordination - Help organize pathology reports, imaging, and laboratory results for clinic review before travel.
If you are exploring hematologic malignancy care in Beijing, you can begin by sharing your case with Best Clinic Abroad and receive guided support in choosing a suitable clinic and planning your next steps.
Question: What risks are associated with hematologic malignancy treatment
Answer: Risks can include infection, immune reactions, and delayed recovery, which clinics manage through monitoring, supportive care, and strict safety protocols.
Question: How long do patients usually stay in Beijing for treatment
Answer: Length of stay varies by treatment type and response, ranging from several weeks to a few months depending on therapy intensity and recovery progress.